Boston, Massachusetts, United States, April 2025 – Pauline Dufresne has taken on a new role as Chief People Officer at Bicara Therapeutics, a clinical-stage biotech company focused on developing innovative immuno-oncology therapies. In her new position, Pauline will be responsible for leading the company’s people strategy and shaping a high-performance culture as the organization continues its clinical development journey.
Before joining Bicara, Pauline served as Vice President, People at X4 Pharmaceuticals, where she led the HR function during a pivotal growth phase, helping the company scale from 70 to 140 employees and navigate its transition from a pre-commercial to commercial-stage biotech. Under her leadership, X4 was recognized as one of the Boston Globe’s Top Places to Work in 2023.
Earlier, Pauline spent nearly six years at Novartis Institutes for BioMedical Research, progressing from HR Business Partner to Global HR Business Partner, Director, where she supported large-scale organizational change and talent strategies across global teams.
Prior to her time at Novartis, she spent close to seven years at Orano (formerly AREVA) in France, where she held several HR leadership roles including HR Development Manager, HR Business Partner for International Projects, and Deputy HR Manager overseeing cross-functional teams across international operations.
Pauline began her HR career at Framatome and Areva, gaining valuable experience in talent management, employee engagement, and internal transformation projects. She currently also serves as a Board Member and HR Committee Member at the Community Music Center of Boston, further demonstrating her commitment to inclusive leadership and community development.
About Bicara Therapeutics:
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class dual-action biologics that combine the precision of targeted therapy with the power of tumor modulators. By delivering immunomodulatory payloads directly to the tumor microenvironment, Bicara aims to activate immune responses and offer long-lasting efficacy in treating cancer. The company is driven by a mission to harness novel biologic approaches to redefine standards of care in oncology.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
